Diffusion Pharmaceuticals Inc. [NASDAQ: DFFN] closed the trading session at $1.07 on 03/18/21. The day’s price range saw the stock hit a low of $1.04, while the highest price level was $1.12. The company report on March 18, 2021 that Diffusion Pharmaceuticals Doses First Participants in TCOM Study.
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced that it has dosed the first participants in the Company’s Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (“TSC”), utilizing a transcutaneous oxygen monitoring (TCOM) device to evaluate the effects of TSC on peripheral tissue oxygenation.
The TCOM trial is the first in a series of three, short-term studies Diffusion plans to conduct in the United States in 2021. Together, the oxygenation trials, which the Company plans to fund with cash-on-hand, will serve as a prospective exploration of the relationship between the level of TSC exposure (dose) and response (change in oxygenation). The results will be used to inform the next phases of clinical development and commercialization plans.
The stocks have a year to date performance of 34.59 percent and weekly performance of 4.90 percent. The stock has been moved at 18.61 percent over the last six months. The stock has performed -28.19 percent around the most recent 30 days and changed 50.70 percent over the most recent 3-months.
If compared to the average trading volume of 8.04M shares, DFFN reached to a volume of 5126683 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Diffusion Pharmaceuticals Inc. [DFFN]:
H.C. Wainwright have made an estimate for Diffusion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 17, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 21, 2018, representing the official price target for Diffusion Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Diffusion Pharmaceuticals Inc. is set at 0.14 The Price to Book ratio for the last quarter was 2.38, with the Price to Cash per share for the same quarter was set at 0.21.
DFFN stock trade performance evaluation
Diffusion Pharmaceuticals Inc. [DFFN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.90. With this latest performance, DFFN shares dropped by -28.19% in over the last four-week period, additionally plugging by 18.61% over the last 6 months – not to mention a rise of 284.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DFFN stock in for the last two-week period is set at 49.27, with the RSI for the last a single of trading hit 51.51, and the three-weeks RSI is set at 49.36 for Diffusion Pharmaceuticals Inc. [DFFN]. The present Moving Average for the last 50 days of trading for this stock 1.1561, while it was recorded at 1.0480 for the last single week of trading, and 0.9761 for the last 200 days.
Diffusion Pharmaceuticals Inc. [DFFN]: An insightful look at the core fundamentals
Diffusion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.40 and a Current Ratio set at 8.40.
Earnings per share (EPS) analysis for Diffusion Pharmaceuticals Inc. [DFFN] stock
With the latest financial reports released by the company, Diffusion Pharmaceuticals Inc. posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DFFN.
Diffusion Pharmaceuticals Inc. [DFFN]: Insider Ownership positions
There are presently around $5 million, or 6.60% of DFFN stock, in the hands of institutional investors. The top three institutional holders of DFFN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 2,832,739, which is approximately -5.214% of the company’s market cap and around 0.21% of the total institutional ownership; BLACKROCK INC., holding 830,471 shares of the stock with an approximate value of $0.89 million in DFFN stocks shares; and VANGUARD GROUP INC, currently with $0.42 million in DFFN stock with ownership of nearly 11.624% of the company’s market capitalization.
9 institutional holders increased their position in Diffusion Pharmaceuticals Inc. [NASDAQ:DFFN] by around 345,375 shares. Additionally, 13 investors decreased positions by around 527,392 shares, while 7 investors held positions by with 4,077,383 shares. The mentioned changes placed institutional holdings at 4,950,150 shares, according to the latest SEC report filing. DFFN stock had 5 new institutional investments in for a total of 267,889 shares, while 8 institutional investors sold positions of 342,505 shares during the same period.